Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exelixis, Inc. - Common Stock (NQ: EXEL )

35.07 +0.87 (+2.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
6 Analysts Have This to Say About Exelixis
Via Benzinga
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
From Exelixis, Inc.
Via Business Wire
Four Undervalued Healthcare Stocks for 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. 
Via MarketBeat
Exposures COVID-19
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —
From Exelixis, Inc.
Via Business Wire
Is Exelixis Stock a Buy Now?
Don't be too quick to dismiss this company as a one-trick pony. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About Exelixis
Via Benzinga
Where Exelixis Stands With Analysts
Via Benzinga
What 4 Analyst Ratings Have To Say About Exelixis
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter: 
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
From Exelixis, Inc.
Via Business Wire
2 Beaten-Down Growth Stocks to Buy Before the Bull Run
These could become hot buys once investors pivot back to growth stocks. 
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint. 
Via The Motley Fool
Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip
These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite. 
Via The Motley Fool
Exelixis Inks Two Licensing Pacts For Cancer Programs
Via Benzinga
Exelixis (EXEL) Q3 2022 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
From Exelixis, Inc.
Via Business Wire
3 Stocks to Buy Hand Over Fist in December
These stocks could be big winners. 
Via The Motley Fool
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
From Exelixis, Inc.
Via Business Wire
Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right
Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks. 
Via The Motley Fool
The Smartest Stocks to Buy With $20 Right Now
You don't need a mountain of cash to begin building wealth on Wall Street. 
Via The Motley Fool
2 No-Brainer Stocks to Buy Right Now for Less than $20
These stocks are still bargain-priced but benefit from long-term trends. 
Via The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
Here's Why This Growth Stock Is Already My 2022 Winner
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter. 
Via The Motley Fool
Looking Into Exelixis's Return On Invested Capital
Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters. 
Via Benzinga
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
From Exelixis, Inc.
Via Business Wire
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
From Exelixis, Inc.
Via Business Wire
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.